Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Abacavir lamivudine zidovudine drug interactions
Introduction
Drug Interactions
Drug Interactions
No drug interaction trials have been conducted using TRIZIVIR Tablets [see Clinical Pharmacology (12.3)].
Antiretroviral Agents
Zidovudine:Stavudine: Concomitant use of Zidovudine with Stavudine should be avoided since an antagonistic relationship has been demonstrated in vitro.
Nucleoside Analogues Affecting DNA Replication: Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the in vitro antiviral activity of Zidovudine against HIV-1; concomitant use of such drugs should be avoided.
Doxorubicin
Zidovudine: Concomitant use of Zidovudine with doxorubicin should be avoided since an antagonistic relationship has been demonstrated in vitro.
Ethanol
Abacavir: Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of Abacavir causing an increase in overall exposure [see Clinical Pharmacology (12.3)].
Hematologic/Bone Marrow Suppressive/Cytotoxic Agents
Zidovudine: Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of Zidovudine.
Interferon- and ribavirin-Based Regimens
Lamivudine: Although no evidence of a pharmacokinetic or pharmacodynamic interaction (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with Lamivudine in HIV-1/HCV co-infected subjects, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected subjects receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin [see Warnings and Precautions (5.6), Clinical Pharmacology (12.3)].
Methadone
Abacavir: The addition of methadone has no clinically significant effect on the pharmacokinetic properties of Abacavir. In a trial of 11 HIV-1-infected subjects receiving methadone-maintenance therapy with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased [see Clinical Pharmacology (12.3)]. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.
Trimethoprim/Sulfamethoxazole (TMP/SMX)
Lamivudine: No change in dose of either drug is recommended [see Clinical Pharmacology (12.3)]. There is no information regarding the effect on Lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat PCP.[1]
References
References
- ↑ “TRIZIVIR ([[Abacavir]] SULFATE, [[Lamivudine]], AND [[Zidovudine]]) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY]”. Retrieved 9 January 2014. URL–wikilink conflict (help)
Adapted from the FDA Package Insert.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sophia Saad, Associate Editor – WikiDoc [2]